Germani, M. M., Moretto, R., Stahler, A., Hashimoto, T., Morano, F., Venook, A. P., Stintzing, S., Nakamura, Y., Paolo, G. D., Battaglin, F., Heinrich, K., Muro, K., Bergamo, F., Modest, D. P., Soeda, J., Antoniotti, C., Lenz, H., Yoshino, T., Heinemann, V., Cremolini, C. (2025). Assessing the predictive role of tumor sidedness in
            <i>RAS</i>
            and
            <i>BRAF</i>
            wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3538